CRDF — Cardiff Oncology Balance Sheet
0.000.00%
- $187.60m
- $94.76m
- $0.68m
Annual balance sheet for Cardiff Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 131 | 141 | 105 | 74.8 | 91.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.32 | 0.535 | 0.771 | 0.888 | 1.17 |
Prepaid Expenses | |||||
Total Current Assets | 133 | 146 | 111 | 77.4 | 95.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.967 | 3.18 | 3.52 | 2.95 | 2.07 |
Other Long Term Assets | |||||
Total Assets | 135 | 150 | 116 | 81.6 | 97.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.12 | 6.56 | 7.81 | 10.4 | 13.4 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.57 | 9.13 | 9.85 | 11.9 | 14.2 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 128 | 140 | 106 | 69.7 | 82.9 |
Total Liabilities & Shareholders' Equity | 135 | 150 | 116 | 81.6 | 97.2 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |